With minimal blood loss and scarring, and faster recovery period, robotic surgeries are becoming game changers in the ...

Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified ...

Chemotherapy has been known to cause damage to peripheral nerves, and sometimes the pain is chronic and severe enough that chemotherapy doses are reduced or discontinued. But prior research has not ...

Recent advancements in imaging techniques and the use of neoadjuvant chemotherapy (NCT) are reshaping how colon cancer is diagnosed and treated. Neoadjuvant chemotherapy refers to the ...

In a nutshell A common desert plant called Artemisia herba-alba contains compounds that can effectively kill colorectal ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients found that patients with evidence of residual cancer in their blood after surgery to remove the cancer, may benefit ...

Patients who had positive ctDNA tests after surgery were almost twice as likely to be alive at 3 years if they received ...

Artemisia herba-alba shows promise in combating colorectal cancer, offering new hope through its powerful medicinal ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ ...